Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Le Fur

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Therapie|February 5, 2017
What is the budget impact of a new treatment or new health technology arriving on the market?Benoit Dervaux, Camille Le Fur, Sophie Dubois, et al.
Therapie|January 28, 2017
Benoit Dervaux, Camille Le Fur, Sophie Dubois, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation scheduleFrancis Fagnani, Camille Le Fur, Isabelle Durand, et al.
Therapie|February 4, 2018
Care pathway, towards the establishment of tailored funding: Reasons and criteria for successGrégory Emery, Camille Le Fur, Anne-Aurélie Epis-de-Fleurian, et al.
Therapie|January 13, 2018
Grégory Emery, Camille Le Fur, Anne-Aurélie Epis-de-Fleurian, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 12, 2008
Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in FranceIsmail Elalamy, Gregoire Le Gal, Fatima Nachit-Ouinekh, et al.
World Journal of Urology|September 6, 2011
Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasiaRichard-Olivier Fourcade, François Lacoin, Morgan Rouprêt, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Therapie|February 5, 2017
What is the budget impact of a new treatment or new health technology arriving on the market?Benoit Dervaux, Camille Le Fur, Sophie Dubois, et al.
Therapie|January 28, 2017
Benoit Dervaux, Camille Le Fur, Sophie Dubois, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation scheduleFrancis Fagnani, Camille Le Fur, Isabelle Durand, et al.
Therapie|February 4, 2018
Care pathway, towards the establishment of tailored funding: Reasons and criteria for successGrégory Emery, Camille Le Fur, Anne-Aurélie Epis-de-Fleurian, et al.
Therapie|January 13, 2018
Grégory Emery, Camille Le Fur, Anne-Aurélie Epis-de-Fleurian, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 12, 2008
Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in FranceIsmail Elalamy, Gregoire Le Gal, Fatima Nachit-Ouinekh, et al.
World Journal of Urology|September 6, 2011
Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasiaRichard-Olivier Fourcade, François Lacoin, Morgan Rouprêt, et al.
Pageof 1